Clinical Trial Update: [18F]FES PET/CT in Endocrine Refractory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating [18F]fluoroestradiol PET/CT imaging in estrogen receptor-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• [18F]FES PET/CT (fluoroestradiol PET/CT imaging agent)

Snippet

Sponsor: University of Pennsylvania | Conditions: Estrogen Receptor Positive Breast Cancer, Breast Neoplasm | Phase 2 | Status: COMPLETED